Semaglutide vs Tirzepatide: Which Is Right for You?

Both are once-weekly injections. Both are prescribed for weight loss. Both are offered at Mirror Mirror Med Spa. But they are not the same drug, and the differences — how much weight you lose, how you tolerate it, what it costs, and what we know about long-term safety — are exactly what should drive your choice.

One Receptor vs Two

Semaglutide — sold as Wegovy for weight management and Ozempic for type 2 diabetes — is a GLP-1 receptor agonist. It mimics a single gut hormone, glucagon-like peptide-1, that tells your brain you are full, slows how fast your stomach empties, and helps your pancreas release insulin when blood sugar rises.

Tirzepatide — sold as Zepbound for weight management and Mounjaro for diabetes — does that and one more thing. It is a dual agonist: it activates the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide). Hitting both pathways produces a stronger effect on fullness and blood-sugar control, which is why tirzepatide's trial results are consistently higher.

That is the whole mechanical difference. Everything else — dosing schedule, side effects, who qualifies — flows from it.

Semaglutide

The proven original

Single GLP-1 agonist. Longest track record of the two, with major trials showing reduced heart-attack and stroke risk.

• Average loss: ~10–15% of body weight
• Weekly injection (a daily pill form also exists)
• Mature cardiovascular safety data
• Generally the lower-cost option
• Brand names: Wegovy, Ozempic

Tirzepatide

The stronger newcomer

Dual GIP + GLP-1 agonist. Higher average weight loss in head-to-head trials; heart-outcome studies are newer and still maturing.

• Average loss: ~15–22% of body weight
• Weekly injection only
• Better blood-sugar reduction
• Newer, more complex to manufacture — costs more
• Brand names: Zepbound, Mounjaro

How They Compare on What Matters

When Semaglutide Is the Better Choice

• You have a moderate amount of weight to lose and a 10–15% reduction would reach your goal
• You have existing cardiovascular risk and want the drug with the most heart-outcome evidence
• Budget matters and you want the more affordable long-term option
• You would prefer a daily pill to a weekly injection (semaglutide is the only one with an oral form)
• You want the medication with the longest real-world track record

When Tirzepatide Is the Better Choice

• You have a larger amount of weight to lose and want the highest average result
• You also have type 2 diabetes or prediabetes — tirzepatide's blood-sugar effect is stronger
• You tried semaglutide and plateaued short of your goal
• Cost is not the deciding factor
• You are comfortable with a newer drug whose long-term data is still building

Which One Makes You Less Sick?

Neither, reliably. This surprises people. Both drugs cause the same cluster of digestive effects — nausea, vomiting, constipation or diarrhea, bloating, reflux — because both slow the stomach. In practice, how sick someone feels depends far more on how quickly the dose is increased than on which molecule they are taking. Both start at a low dose and step up every few weeks; a provider who titrates slowly and holds a dose when you are struggling will get you through the adjustment period on either drug.

What Weight Loss Looks Like Month by Month

Both medications follow a similar curve. The first three months are the fastest — appetite drops sharply and many people lose 8–12% of their starting weight, often 10 pounds in the first month. Months three through twelve are where the bulk of the loss happens, settling into a steady one to two pounds a week. Tirzepatide's curve is steeper at every point; the gap between the two drugs widens the longer you stay on them. People with type 2 diabetes tend to lose slightly less on either drug than people without it.

The part nobody advertises: stopping either medication usually leads to progressive regain. These are long-term treatments for a chronic condition, not a three-month reset. Protein intake and resistance training matter throughout, because rapid loss on any GLP-1 includes some lean muscle unless you actively protect it.

Who Qualifies for Either One

The criteria are the same for both drugs. You typically qualify with a BMI of 30 or higher, or a BMI of 27–29.9 plus at least one weight-related condition — high blood pressure, type 2 diabetes or prediabetes, high cholesterol, sleep apnea, PCOS, or fatty liver disease. You are not a candidate if you or a close family member has had medullary thyroid carcinoma or MEN 2, if you have a history of pancreatitis, or if you are pregnant, planning to become pregnant, or breastfeeding. Your provider screens for all of this at your first visit. Full detail is on our medical weight loss candidacy page.

Why Pricing Varies So Much

You will see semaglutide and tirzepatide quoted anywhere from under $100 a month to over $1,300, and every number can be true. Brand-name retail prices without insurance run $1,000–$1,350 a month for either drug. Commercial insurance that covers weight-loss medication — many plans don't — can bring the copay down to $25–$100 with manufacturer savings cards. Direct self-pay programs from the manufacturers sit in between. Semaglutide is generally cheaper than tirzepatide because it has been on the market longer and is simpler to produce.

What Happens to Your Skin and Shape

Losing 15–20% of your body weight in a year changes more than the number on the scale. Skin that stretched over the lost volume does not always retract on its own, particularly on the face, neck, abdomen, and arms. This is why Mirror Mirror pairs the weight-loss program with the treatments that address it — Forma radiofrequency for mild laxity, E-Sculpt for muscle tone as the fat comes off, and Sculptra for facial volume. We wrote a full guide to it in Skin Laxity & Body Contouring After Weight Loss.